Mga Batayang Estadistika
| LEI | 549300TN20OLYTJVP152 |
| CIK | 827871 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Eagle Pharmaceuticals, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| January 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36306 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified |
|
| December 2, 2024 |
AMENDMENT NO. 1 TO RIGHTS AGREEMENT Exhibit 4.1 AMENDMENT NO. 1 TO RIGHTS AGREEMENT This AMENDMENT NO. 1 TO RIGHTS AGREEMENT, dated as of December 2, 2024 (this “Amendment”), is made and entered into by and between Eagle Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Equiniti Trust Company, LLC, a federally chartered trust company, as Rights Agent (the “Rights Agent”). Except as otherwise provided herein, capital |
|
| December 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2024 Eagle Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36306 20-8179278 (State or Other Jurisdiction (Commission File Number) |
|
| November 27, 2024 |
As filed with the Securities and Exchange Commission on November 27, 2024 As filed with the Securities and Exchange Commission on November 27, 2024 Registration No. |
|
| November 27, 2024 |
As filed with the Securities and Exchange Commission on November 27, 2024 As filed with the Securities and Exchange Commission on November 27, 2024 Registration No. |
|
| November 27, 2024 |
Eagle Pharmaceuticals, Inc. 50 Tice Boulevard, Suite 315 Woodcliff Lake, New Jersey 07677 Eagle Pharmaceuticals, Inc. 50 Tice Boulevard, Suite 315 Woodcliff Lake, New Jersey 07677 November 27, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Eagle Pharmaceuticals, Inc. Application for Withdrawal of Registration Statement Form S-3 File No. 333-267827 Ladies and Gentlemen: Reference is made to the registr |
|
| November 27, 2024 |
As filed with the Securities and Exchange Commission on November 27, 2024 As filed with the Securities and Exchange Commission on November 27, 2024 Registration No. |
|
| November 27, 2024 |
As filed with the Securities and Exchange Commission on November 27, 2024 As filed with the Securities and Exchange Commission on November 27, 2024 Registration No. |
|
| November 27, 2024 |
As filed with the Securities and Exchange Commission on November 27, 2024 As filed with the Securities and Exchange Commission on November 27, 2024 Registration No. |
|
| November 27, 2024 |
As filed with the Securities and Exchange Commission on November 27, 2024 POS AM 1 tm2429505d9posam.htm POS AM As filed with the Securities and Exchange Commission on November 27, 2024 Registration No. 333-202592 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-202592 UNDER THE SECURITIES ACT OF 1933 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its c |
|
| November 27, 2024 |
As filed with the Securities and Exchange Commission on November 27, 2024 As filed with the Securities and Exchange Commission on November 27, 2024 Registration No. |
|
| November 27, 2024 |
Exhibit 16.1 November 27, 2024 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read Item 4.01 of Form 8-K dated November 27, 2024, of Eagle Pharmaceuticals, Inc. (the “Company”) and are in agreement with the statements contained in in the first sentence of the first paragraph, the second paragraph, all but the third sentence of the third paragraph |
|
| November 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2024 Eagle Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36306 20-8179278 (State or Other Jurisdiction (Commission File Number |
|
| November 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-36306 Eagle Pharmaceutical, Inc. The Nasdaq Stock Market LLC (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered |
|
| November 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2024 Eagle Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36306 20-8179278 (State or Other Jurisdiction (Commission File Number |
|
| November 13, 2024 |
Cautionary Note Regarding Forward-Looking Statements UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 001-36306 CUSIP NUMBER 269796108 NOTIFICATION OF LATE FILING (Check One): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-CEN ¨ Form N-CSR For Period Ended: September 30, 2024 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Tr |
|
| November 12, 2024 |
EGRX / Eagle Pharmaceuticals, Inc. / CITIGROUP INC - SC 13G Passive Investment SC 13G 1 sc13geaglepharmaceut.htm SC 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (AMENDMENT NO. )* Eagle Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 269796-10-8 (CUSIP Number |
|
| November 12, 2024 |
Eagle Pharmaceuticals Appoints Christopher Krawtschuk as Chief Financial Officer Exhibit 99.1 Eagle Pharmaceuticals Appoints Christopher Krawtschuk as Chief Financial Officer WOODCLIFF LAKE, N.J. — November 12, 2024 — Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced the appointment of Christopher Krawtschuk as Chief Financial Officer (“CFO”) of the Company, effective November 11, 2024. In connection with Mr. Krawtschuk’s appointment, Mr. S |
|
| November 12, 2024 |
Exhibit 10.1 November 8, 2024 Christopher Krawtschuk 490 Foothill Road Bridgewater, NJ 08807 Re: Offer of Employment Dear Christopher: I am pleased to offer you an initial position with Eagle Pharmaceuticals, Inc. (the “Company”), as its Chief Financial Officer in the Company’s New Jersey office. If you commence employment with the Company pursuant to the terms of this offer letter and su |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2024 Eagle Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36306 20-8179278 (State or Other Jurisdiction (Commission (IRS Employe |
|
| November 5, 2024 |
EGRX / Eagle Pharmaceuticals, Inc. / Nantahala Capital Management, LLC - SC 13G/A Passive Investment SC 13G/A 1 tm2427463d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* EAGLE PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 269796108 (CUSIP Number) October 31, 2024 (Date of Event which Requires Filing of this Statemen |
|
| October 31, 2024 |
Exhibit 3.1 CERTIFICATE OF DESIGNATION OF RIGHTS, PREFERENCES AND PRIVILEGES OF SERIES A JUNIOR PARTICIPATING PREFERRED STOCK OF EAGLE PHARMACEUTICALS, INC. The undersigned, Michael Graves, does hereby certify: 1. That he is duly elected and acting Interim Principal Executive Officer of Eagle Pharmaceuticals, Inc. a Delaware corporation (the “Corporation”). 2. That pursuant |
|
| October 31, 2024 |
EAGLE PHARMACEUTICALS ADOPTS LIMITED DURATION STOCKHOLDER RIGHTS PLAN Exhibit 99.1 EAGLE PHARMACEUTICALS ADOPTS LIMITED DURATION STOCKHOLDER RIGHTS PLAN WOODCLIFF LAKE, New Jersey, October 31, 2024 – Eagle Pharmaceuticals, Inc. (the “Company” or “Eagle”) (OTCMKTS: EGRX) today announced that its Board of Directors (the “Board”) has adopted a limited duration stockholder rights agreement (the “Rights Plan”), effective immediately. The Company continues to experience a |
|
| October 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2024 Eagle Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36306 20-8179278 (State or Other Jurisdiction (Commission (IRS Employe |
|
| October 31, 2024 |
EGRX / Eagle Pharmaceuticals, Inc. / Union Square Park Capital Management, LLC Passive Investment SC 13G/A 1 unionsquare-egrx103024a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* EAGLE PHARMACEUTICALS, INC. (Name of Issuer) Common stock, $0.001 par value per share (Title of Class of Securities) 269796108 (CUSIP Number) October 30, 2024 (Date of Event Which Requires Filing of this Statement) |
|
| October 31, 2024 |
Exhibit 4.1 EAGLE PHARMACEUTICALS, INC. and EQUINITI TRUST COMPANY, LLC, as Rights Agent RIGHTS AGREEMENT October 30, 2024 Table of Contents Page Section 1. Certain Definitions 1 Section 2. Appointment of Rights Agent 9 Section 3. Issuance of Rights 9 Section 4. Form of Right Certificates 11 Section 5. Countersignature and Registration 12 Section 6. Transfer, Split Up, Combination and Exchange of |
|
| October 9, 2024 |
EGRX / Eagle Pharmaceuticals, Inc. / HIRSCHMAN ORIN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 1 Under the Securities Exchange Act of 1934 EAGLE PHARMACEUTICALS INC. (Name of Issuer) Common Stock (Title of Class of Securities) 269796108 (CUSIP Number) October 2, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| October 8, 2024 |
EGRX / Eagle Pharmaceuticals, Inc. / Union Square Park Capital Management, LLC Passive Investment SC 13G 1 unionsquare-egrx100324.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* EAGLE PHARMACEUTICALS, INC. (Name of Issuer) Common stock, $0.001 par value per share (Title of Class of Securities) 269796108 (CUSIP Number) October 3, 2024 (Date of Event Which Requires Filing of this Statement) Check t |
|
| October 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2024 Eagle Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36306 20-8179278 (State or Other Jurisdiction (Commission (IRS Emplo |
|
| August 27, 2024 |
LIMITED WAIVER AND FOURTH AMENDMENT TO THIRD AMENDED AND RESTATED CREDIT AGREEMENT Exhibit 10.1 EXECUTION VERSION LIMITED WAIVER AND FOURTH AMENDMENT TO THIRD AMENDED AND RESTATED CREDIT AGREEMENT This LIMITED WAIVER AND FOURTH AMENDMENT TO THIRD AMENDED AND RESTATED CREDIT AGREEMENT (this “Agreement”) is made as of August 26, 2024 by and among Eagle Pharmaceuticals, Inc., a Delaware corporation (the “Borrower”), the financial institutions listed on the signature pages hereto an |
|
| August 27, 2024 |
Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq Exhibit 99.1 Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq WOODCLIFF LAKE, N.J., August 27, 2024 (GLOBE NEWSWIRE) - Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (the “Company” or “Eagle”) today announced that it received a notice (the “Notice”) on August 21, 2024, from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) advisi |
|
| August 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2024 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Numbe |
|
| August 9, 2024 |
Cautionary Note Regarding Forward-Looking Statements UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 001-36306 CUSIP NUMBER 269796108 NOTIFICATION OF LATE FILING (Check One): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-CEN ¨ Form N-CSR For Period Ended: June 30, 2024 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transi |
|
| August 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2024 Eagle Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36306 20-8179278 (State or Other Jurisdiction (Commission (IRS Employer |
|
| July 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2024 Eagle Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36306 20-8179278 (State or Other Jurisdiction (Commission (IRS Employer of |
|
| July 3, 2024 |
EGRX / Eagle Pharmaceuticals, Inc. / Nantahala Capital Management, LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* EAGLE PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 269796108 (CUSIP Number) June 30, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| May 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2024 Eagle Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36306 20-8179278 (State or Other Jurisdiction (Commission (IRS Employer of |
|
| May 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2024 Eagle Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36306 20-8179278 (State or Other Jurisdiction (Commission (IRS Employer of |
|
| May 22, 2024 |
Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq Exhibit 99.1 Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq WOODCLIFF LAKE, N.J. — May 22, 2024 — Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (the “Company” or “Eagle”) today announced that it received a notice (the “Notice”) on May 20, 2024, from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it |
|
| May 15, 2024 |
THIRD AMENDMENT TO THIRD AMENDED AND RESTATED CREDIT AGREEMENT Exhibit 10.1 THIRD AMENDMENT TO THIRD AMENDED AND RESTATED CREDIT AGREEMENT This THIRD AMENDMENT TO THIRD AMENDED AND RESTATED CREDIT AGREEMENT (this “Agreement”) is made as of May 14, 2024 by and among Eagle Pharmaceuticals, Inc., a Delaware corporation (the “Borrower”), the financial institutions listed on the signature pages hereto and JPMorgan Chase Bank, N.A., as Administrative Agent (the “Ad |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2024 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Number) |
|
| May 10, 2024 |
Cautionary Note Regarding Forward-Looking Statements UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 001-36306 CUSIP NUMBER 269796108 NOTIFICATION OF LATE FILING (Check One): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-CEN ¨ Form N-CSR For Period Ended: March 31, 2024 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transi |
|
| April 12, 2024 |
Exhibit 99.1 Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Form 10-K WOODCLIFF LAKE, N.J. — April 12, 2024 — Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (the “Company”) today announced that it received a notice (the “Notice”) on April 8, 2024 from the Listing Qualifications Department of The Nasdaq Stock Marke |
|
| April 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2024 Eagle Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36306 20-8179278 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 18, 2024 |
Cautionary Note Regarding Forward-Looking Statements UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 001-36306 CUSIP NUMBER 269796108 NOTIFICATION OF LATE FILING (Check One): x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨Form 10-Q ¨ Form 10-D ¨ Form N-CEN ¨ Form N-CSR For Period Ended: December 31, 2023 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Tran |
|
| March 18, 2024 |
EGRX / Eagle Pharmaceuticals, Inc. / Tarriff Scott - SC 13G/A Passive Investment SC 13G/A CUSIP No. 269796108 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 9)* Eagle Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 269796108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Che |
|
| March 8, 2024 |
Exhibit 10.2 March 8, 2024 VIA EMAIL Steven Ratoff Dear Steve: This agreement contains the terms of your position as Interim Chief Financial Officer of Eagle Pharmaceuticals, Inc. (the “Company”) with an effective date of Mach 8, 2024 (the “Effective Date”). As Interim Chief Financial Officer, you will report directly to the Interim Executive Chair and will perform duties of the chief financial of |
|
| March 8, 2024 |
[signatures to follow on next page] Exhibit 10.1 March 8, 2024 Brian Cahill VIA EMAIL Dear Brian: This letter sets forth the substance of the separation agreement (the “Agreement”) that Eagle Pharmaceuticals, Inc. (the “Company”) is offering to you to aid in your employment transition. 1. Resignation and Separation Date. You have tendered and the Company hereby accepts your resignation from your employment with the Company. |
|
| March 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2024 Eagle Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36306 20-8179278 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 1, 2024 |
SECOND AMENDMENT TO THIRD AMENDED AND RESTATED CREDIT AGREEMENT Exhibit 10.1 EXECUTION VERSION SECOND AMENDMENT TO THIRD AMENDED AND RESTATED CREDIT AGREEMENT This SECOND AMENDMENT TO THIRD AMENDED AND RESTATED CREDIT AGREEMENT (this “Agreement”) is made as of February 29, 2024 by and among Eagle Pharmaceuticals, Inc., a Delaware corporation (the “Borrower”), the financial institutions listed on the signature pages hereto and JPMorgan Chase Bank, N.A., as Admi |
|
| March 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 29, 2024 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Num |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Num |
|
| February 14, 2024 |
EGRX / Eagle Pharmaceuticals, Inc. / Graves Michael - SC 13D Activist Investment SC 13D 1 tm246055d1sc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Eagle Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 269796108 (CUSIP Number) Michael Graves c/o Eagle Pharmaceuticals, Inc. 50 Tice Blvd., Suite 315 Woodc |
|
| February 13, 2024 |
EGRX / Eagle Pharmaceuticals, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Eagle Pharmaceuticals Inc/DE Title of Class of Securities: Common Stock CUSIP Number: 269796108 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2024 Eagle Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36306 20-8179278 (State or Other Jurisdiction of Incorporation) (Commi |
|
| February 7, 2024 |
EGRX / Eagle Pharmaceuticals, Inc. / HIRSCHMAN ORIN Passive Investment SC 13G 1 formsc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 EAGLE PHARMACEUTICALS INC. (Name of Issuer) Common Stock (Title of Class of Securities) 269796108 (CUSIP Number) January 31, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| January 18, 2024 |
Eagle Pharmaceuticals Provides Update on Bendamustine Intellectual Property Portfolio Exhibit 99.1 Eagle Pharmaceuticals Provides Update on Bendamustine Intellectual Property Portfolio WOODCLIFF LAKE, N.J. — January 18, 2024 — Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today provided an update on its bendamustine intellectual property portfolio. On January 16, 2024, the United States Court of Appeals for the Federal Circuit affirmed the previously announc |
|
| January 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2024 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction (Commission File Number) |
|
| January 16, 2024 |
LIMITED WAIVER AND FIRST AMENDMENT TO THIRD AMENDED AND RESTATED CREDIT AGREEMENT Exhibit 10.1 LIMITED WAIVER AND FIRST AMENDMENT TO THIRD AMENDED AND RESTATED CREDIT AGREEMENT This LIMITED WAIVER AND FIRST AMENDMENT TO THIRD AMENDED AND RESTATED CREDIT AGREEMENT (this “Agreement”) is made as of January 12, 2024 by and among Eagle Pharmaceuticals, Inc., a Delaware corporation (the “Borrower”), the financial institutions listed on the signature pages hereto and JPMorgan Chase Ba |
|
| January 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2024 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Numb |
|
| December 22, 2023 |
Exhibit 10.1 December 21, 2023 VIA EMAIL Michael Graves Dear Mike: This agreement contains the terms of your position as Interim Principal Executive Officer of Eagle Pharmaceuticals, Inc. (the “Company”) and Interim Executive Chairman (the “Interim Executive Chair”) of the Board of Directors of the Company (the “Board”) with an effective date of November 27, 2023 (the “Effective Date”). As Interim |
|
| December 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 27, 2023 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction (Co |
|
| December 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2023 Eagle Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36306 20-8179278 (State or Other Jurisdiction of Incorporation) (Comm |
|
| December 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2023 Eagle Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36306 20-8179278 (State or Other Jurisdiction of Incorporation) (Commi |
|
| December 6, 2023 |
Exhibit 99.1 Eagle Pharmaceuticals to Present Abstract on Post-hoc Analysis of Amisulpride at the 77th PGA (PostGraduate Assembly in Anesthesiology) in New York City - BARHEMSYS® (amisulpride) Injection is the first and only antiemetic approved by the U.S. Food and Drug Administration (“FDA”) for rescue treatment of postoperative nausea and vomiting (“PONV”) despite prophylaxis1 and is also approv |
|
| November 29, 2023 |
Exhibit 99.1 Eagle Pharmaceuticals Announces Management Change – CEO and Founder Scott Tarriff Retires – – Chairman Michael Graves to Serve as Interim Executive Chairman – WOODCLIFF LAKE, N.J., November 29, 2023 - Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced a change in management. Effective immediately Scott Tarriff, Founder, President and Chief Exec |
|
| November 29, 2023 |
Exhibit 99.1 Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Quarterly Report on Form 10-Q WOODCLIFF LAKE, N.J. — November 29, 2023 — Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (the “Company”) today announced that it received a notice (the “Notice”) on November 27, 2023 from the Listing Qualifications Department of The Nasdaq S |
|
| November 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 27, 2023 Eagle Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36306 20-8179278 (State or Other Jurisdiction of Incorporation) (Comm |
|
| November 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 27, 2023 Eagle Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36306 20-8179278 (State or Other Jurisdiction of Incorporation) (Comm |
|
| November 29, 2023 |
[signatures to follow on next page] Exhibit 10.1 November 27, 2023 Scott Tarriff VIA EMAIL Dear Scott: This letter sets forth the substance of the separation agreement (the “Agreement”) that Eagle Pharmaceuticals, Inc. (the “Company”) is offering to you to aid in your employment transition. This Agreement will become effective on the date it has been signed by both parties (the “Effective Date”). 1. CEO Retirement Date an |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Numb |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 001-36306 CUSIP NUMBER 269796108 NOTIFICATION OF LATE FILING (Check One): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-CEN ¨ Form N-CSR For Period Ended: September 30, 2023 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Tr |
|
| November 9, 2023 |
Eagle Delays Third Quarter 2023 Results and Conference Call Exhibit 99.1 Eagle Delays Third Quarter 2023 Results and Conference Call WOODCLIFF LAKE, NJ—November 9, 2023—Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it will be delaying the release of its third quarter 2023 results and investor conference call, previously scheduled for today, Thursday, November 9, 2023. The Company currently anticipates filing a F |
|
| October 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2023 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Numb |
|
| October 24, 2023 |
Eagle Pharmaceuticals Granted Patent for PEMFEXY® Exhibit 99.1 Eagle Pharmaceuticals Granted Patent for PEMFEXY® WOODCLIFF LAKE, N.J. — October 24, 2023 — Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the U.S. Patent and Trademark Office has granted the Company U.S. Patent No. 11,793,813 (“the ‘813 patent”) entitled “Pemetrexed Formulations.” Eagle has submitted the patent for listing in the U.S. Food |
|
| October 23, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2023 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Numb |
|
| October 23, 2023 |
Exhibit 99.1 Eagle Pharmaceuticals Granted Unique J-Code and Pass-Through Status for BARHEMSYS® from CMS - J-code is effective January 1, 2024, and transitional pass-through status became effective October 1, 2023, facilitating patient access - - BARHEMSYS is the first and only antiemetic approved by the FDA for rescue treatment of postoperative nausea and vomiting (“PONV”) despite prophylaxis1 an |
|
| September 27, 2023 |
Exhibit 99.1 © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 1 © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. Company Overview September 2023 © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 2 Forward - Looking Statements This presentation contains “forward - looking statements” within the meaning of the Private Securities Litigation Reform Act of 19 95, as amended, and oth |
|
| September 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2023 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Nu |
|
| September 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 7, 2023 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Num |
|
| September 7, 2023 |
Exhibit 99.1 © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 1 © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. Company Overview September 2023 © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 2 Forward - Looking Statements This presentation contains “forward - looking statements” within the meaning of the Private Securities Litigation Reform Act of 19 95, as amended, and oth |
|
| August 29, 2023 |
Exhibit 99.1 Eagle Pharmaceuticals Announces Positive Type C Meeting with FDA for EA-114, an Estrogen Receptor Antagonist Used in the Treatment of Metastatic Breast Cancer in Post-Menopausal Women Eagle plans to file a new drug application (“NDA”) for EA-114 in 2024 EA-114 is anticipated to meaningfully optimize the dosing regimen for all fulvestrant patients and provide the opportunity for a more |
|
| August 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2023 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction (Commission File Number) |
|
| August 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 17, 2023 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction (Commission File Number) |
|
| August 17, 2023 |
Exhibit 99.1 Eagle Pharmaceuticals Reiterates 2023 Adjusted non-GAAP EBITDA and Adjusted non-GAAP EPS1 Guidance - FY 2023 Adjusted non-GAAP EBITDA expected to be $78.0 - $84.0 million1 - - FY 2023 Adjusted non-GAAP earnings per share expected to be $4.40 - $4.701 - - Reflects strength of Eagle’s business and product pipeline; Company poised for sustained long-term growth – WOODCLIFF LAKE, N.J. — A |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36306 Eagle Pharmaceutical |
|
| August 8, 2023 |
Exhibit 99.1 Eagle Pharmaceuticals Reports Second Quarter 2023 Results · Total revenue for Q2 2023 was $64.6 million · Q2 2023 net income was $0.39 per basic and diluted share and adjusted non-GAAP net income1 was $1.18 per basic and diluted share · Q2 2023 net income was $5.2 million · Q2 2023 adjusted non-GAAP EBITDA1 was $20.7 million · Gross margin was 74% for the first half of 2023, up from 7 |
|
| August 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction (Commission File Number) ( |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36306 Eagle Pharmaceuticals, |
|
| July 31, 2023 |
Exhibit 99.1 For Immediate Release Eagle Pharmaceuticals Raises 2023 Adjusted non-GAAP EPS1 Guidance - FY 2023 Adjusted non-GAAP earnings per share now expected to be $4.40 - $4.701 - - FY 2023 Adjusted non-GAAP EBITDA expected to be $78.0 - $84.0 million1 - - FY 2023 Adjusted non-GAAP R&D expense is reiterated at $41.0-$45.0 million1 - - FY 2023 Adjusted non-GAAP SG&A expense is reiterated at $86 |
|
| July 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2023 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction (Commission File Number) (I |
|
| July 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2023 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction (Commission File Number) (I |
|
| July 24, 2023 |
Exhibit 99.1 For Immediate Release Eagle Pharmaceuticals Announces First Patient Randomized in Phase 2 Study Evaluating CAL02, a Novel First-in-Class Anti-Toxin Drug Candidate, in Severe Community-Acquired Bacterial Pneumonia (SCABP) Despite the availability of antibiotics, the death rate from pneumonia in the U.S. has seen little improvement in the past half century1 - CAL02 is a unique therapeut |
|
| July 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2023 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction (Commission File Number) (I |
|
| July 7, 2023 |
EGRX / Eagle Pharmaceuticals Inc / BlackRock Inc. Passive Investment us2697961082070723.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 10) EAGLE PHARMACEUTICALS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 269796108 - (CUSIP Number) June 30, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan |
|
| June 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2023 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction (Commission File Number) (I |
|
| June 15, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Number) |
|
| June 15, 2023 |
Eagle Pharmaceuticals Provides Business Update and Reiterates 2023 Guidance EX-99.1 2 tm2318779d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Eagle Pharmaceuticals Provides Business Update and Reiterates 2023 Guidance WOODCLIFF LAKE, N.J. — June 15, 2023 — Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today provided a business update and reiterated its 2023 financial guidance. “As we approach midyear 2023, our business remains strong, and we are pleased wi |
|
| June 14, 2023 |
Exhibit 99.1 Eagle Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) and Fast-Track Designation for CAL02, Providing Five-Year Exclusivity Extension With QIDP, Eagle expects to receive eight or ten years of regulatory exclusivity upon NDA approval - Company believes CAL02 is a new chemical entity (NCE), which would result in five years of marketing exclusivity upon approval |
|
| June 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Number) |
|
| June 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2023 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Number) |
|
| June 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2023 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Number) |
|
| June 7, 2023 |
Exhibit 99.1 © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 1 © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. Company Overview June 2023 © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 2 Forward - Looking Statements This presentation contains “forward - looking statements” within the meaning of the Private Securities Litigation Reform Act of 19 95, as amended, and other se |
|
| May 9, 2023 |
Exhibit 99.1 For Immediate Release Eagle Pharmaceuticals Reports First Quarter 2023 Results · Total revenue for Q1 2023 was $66.3 million, compared to $115.9 million in Q1 2022 · Q1 2023 net income was $0.44 per basic and diluted share and adjusted non-GAAP net income1 was $1.27 per basic and $1.26 per diluted share · Q1 2023 adjusted non-GAAP EBITDA of $22.3 million · Q1 2023 net sales of PEMFEXY |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Number) ( |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36306 Eagle Pharmaceuticals |
|
| May 1, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by R |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2023 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Number) ( |
|
| May 1, 2023 |
Exhibit 99.1 Eagle Pharmaceuticals Granted Unique J-Code for Byfavo®1 (remimazolam for injection) from CMS - Byfavo1 is indicated for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less WOODCLIFF LAKE, N.J. — May X, 2023 — Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the Centers for Medicare & |
|
| April 10, 2023 |
Exhibit 10.1 Certain information marked as [***] has been excluded from this exhibit because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential. SETTLEMENT AND LICENSE AGREEMENT This SETTLEMENT AND LICENSE AGREEMENT (this “Agreement”) is hereby entered into and made effective on April 4, 2023 (the “Effective Date”) by and among, on the one hand, Tev |
|
| April 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2023 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Number) |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-36306 Eagle Pharmac |
|
| March 23, 2023 |
List of subsidiaries of Eagle Pharmaceuticals, Inc. Exhibit 21.1 Subsidiaries of Eagle Pharmaceuticals, Inc. Name of Subsidiary Jurisdiction of Incorporation Eagle Biologics, Inc. (formerly Arsia Therapeutics, Inc.) Delaware Eagle Research Lab Limited Malta Acacia Pharma Group plc United Kingdom Acacia Pharma Limited United Kingdom Acacia Pharma Inc Delaware |
|
| March 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 001-36306 CUSIP NUMBER 269796108 NOTIFICATION OF LATE FILING (Check One): x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N-CEN ¨ Form N-CSR For Period Ended: December 31, 2022 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Tra |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2023 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Number |
|
| March 13, 2023 |
Exhibit 99.1 Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Results · Q4 2022 net income was $0.63 per basic and $0.62 per diluted share and adjusted non-GAAP net income was $1.11 per basic and $1.10 per diluted share1 · Total revenue for Q4 2022 was $60.7 million, compared to $42.3 million in Q4 2021 · FY 2022 net income was $2.76 per basic and $2.73 per diluted share and adjuste |
|
| February 14, 2023 |
EGRX / Eagle Pharmaceuticals Inc / Tarriff Scott - AMENDMENT TO FOR SC 13G Passive Investment SC 13G/A 1 tarriffsc13ga-123122.htm AMENDMENT TO FOR SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 8)* Eagle Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 269796108 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Fi |
|
| February 9, 2023 |
EGRX / Eagle Pharmaceuticals Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Eagle Pharmaceuticals Inc./DE Title of Class of Securities: Common Stock CUSIP Number: 269796108 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| January 10, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2023 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Numb |
|
| January 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Num |
|
| January 10, 2023 |
Exhibit 99.1 © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 1 © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. Company Overview J.P. Morgan Healthcare Conference January 2023 © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 2 Forward - Looking Statements This presentation contains “forward - looking statements” within the meaning of the Private Securities Litigation Reform A |
|
| January 10, 2023 |
Eagle Pharmaceuticals Provides Business Update and Guidance for 2023 Exhibit 99.1 Eagle Pharmaceuticals Provides Business Update and Guidance for 2023 Woodcliff Lake, N.J. – January 10, 2023 - Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today provided a business update and guidance for 2023. Highlights: · During the 12 months ended September 30, 2022, Eagle recorded net income of $21.3 million or $1.63 per diluted share and adjusted EBITDA |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Numbe |
|
| January 9, 2023 |
EX-99.1 2 tm232671d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 1 © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. Company Overview J.P. Morgan Healthcare Conference January 2023 © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 2 Forward - Looking Statements This presentation contains “forward - looking statements” within the meaning o |
|
| December 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2022 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Num |
|
| December 19, 2022 |
Exhibit 99.1 Eagle Pharmaceuticals Receives FDA Approval for Additional Indication for PEMFEXY® in Combination with Pembrolizumab and Platinum Chemotherapy - Additional indication is for the initial treatment of patients with metastatic, non-squamous, non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations - - Represents the fifth indication for PEMFEXY, a ready-to-use liquid with |
|
| December 14, 2022 |
Exhibit 10.1 AMENDMENT TO DEVELOPMENT AND LICENSING AGREEMENT THIS AMENDMENT TO THE DEVELOPMENT AND LICENSING AGREEMENT (the ?Amendment?) is made as of December 9, 2022 (the ?Amendment Date?) and effective as of October 1, 2022, by and between Eagle Pharmaceuticals, Inc. (?Eagle?), and Robert One, LLC, (?Robert One?), and amends the February 13, 2009 Development and Licensing Agreement, by and bet |
|
| December 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2022 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Numb |
|
| December 12, 2022 |
Exhibit 99.1 Eagle Pharmaceuticals Reaches Settlement Agreement with Accord Healthcare, Inc. Related to BENDEKA® (bendamustine hydrochloride) Woodcliff Lake, N.J. – December 12, 2022 - Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it has reached a settlement agreement with Accord Healthcare, Inc. (“Accord”). Eagle had asserted its Orange Book-listed pat |
|
| December 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2022 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Numb |
|
| December 9, 2022 |
Exhibit 10.1 Eagle Pharmaceuticals, Inc. Amended and Restated Severance Benefit Plan Section 1.??????????????Introduction. The Eagle Pharmaceuticals, Inc. Amended and Restated Severance Benefit Plan (the ?Plan?) was originally established effective as of December 10, 2019, and amended effective as of December 9, 2022 (the ?Effective Date?). The purpose of the Plan is to provide for the payment of |
|
| December 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2022 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Numb |
|
| December 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2022 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Numb |
|
| December 6, 2022 |
Exhibit 99.1 2022 Eagle Pharmaceuticals, Inc. All rights reserved. 1 2022 Eagle Pharmaceuticals, Inc. All rights reserved. December 6, 2022Investor Day 2022 Eagle Pharmaceuticals, Inc. All rights reserved. 2 Forward-Looking StatementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and other securities law |
|
| November 14, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Num |
|
| November 14, 2022 |
Exhibit 99.1 For Immediate Release Eagle Pharmaceuticals Announces FDA Acceptance of Investigational New Drug Application for CAL02, a Novel First-in-Class Broad-Spectrum Anti-Virulence Agent for the Adjunct Treatment of Severe Community-Acquired Bacterial Pneumonia - Expect to begin a Phase 2 study in approximately 276 patients with severe community- acquired pneumonia at approximately 120 sites |
|
| November 9, 2022 |
Settlement and License Agreement, by and between Teva Pharmaceuticals International GmbH Exhibit 10.4 Execution Copy SETTLEMENT AND LICENSE AGREEMENT This SETTLEMENT AND LICENSE AGREEMENT (this ?Agreement?) is hereby entered into and made effective on April 18, 2022 (the ?Effective Date?) by and among, on the one hand, Teva Pharmaceuticals International GmbH (?Teva GmbH?) and Cephalon, Inc. (?Cephalon,? together with Teva GmbH, ?Teva?), and Eagle Pharmaceuticals, Inc., (?Eagle,? toget |
|
| November 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2022 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Nu |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36306 Eagle Pharmaceuti |
|
| November 9, 2022 |
Exhibit 99.1 For Immediate Release Correcting & Replacing: Eagle Pharmaceuticals Reports Third Quarter 2022 Results Eagle Pharmaceuticals, Inc. is re-issuing in its entirety its earnings press release for the third quarter ended September 30, 2022, originally issued on November 7, 2022 at 6:50 am ET, to correct errors in the presentation of certain line items in the financial statements included t |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2022 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Numb |
|
| November 7, 2022 |
Exhibit 99.1 For Immediate Release Eagle Pharmaceuticals Reports Third Quarter 2022 Results ? Q3 2022 net loss was $(0.27) per basic and diluted share and adjusted non-GAAP net income was $1.13 per basic and $1.12 per diluted share1 ? Total revenue for Q3 2022 was $65.9 million, compared to $39.9 million in Q3 2021 ? Nine-month 2022 net income was $2.41 per basic and $2.38 per diluted share ? Nine |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2022 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Numb |
|
| November 3, 2022 |
Exhibit 10.1 ? EXECUTION VERSION ? ? ? THIRD AMENDED AND RESTATED CREDIT AGREEMENT ? dated as of ? November?1, 2022 ? among ? EAGLE PHARMACEUTICALS,?INC. ? The Lenders Party Hereto ? JPMORGAN CHASE BANK, N.A., as Administrative Agent ? and ? CITIZENS BANK, N.A., as Documentation Agent ? ? ? JPMORGAN CHASE BANK, N.A., as Sole Bookrunner and Sole Lead Arranger ? ? ? ? ? Table of Contents ? Page ? AR |
|
| October 17, 2022 |
Eagle Pharmaceuticals, Inc. 50 Tice Boulevard, Suite 315 Woodcliff Lake, New Jersey 07677 Eagle Pharmaceuticals, Inc. 50 Tice Boulevard, Suite 315 Woodcliff Lake, New Jersey 07677 October 17, 2022 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Alan Campbell Re: Eagle Pharmaceuticals, Inc. Registration Statement on Form S-3 (File No. 333-267827) Request for Acceleration of Effective Date Mr. Campbell: In |
|
| October 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 12, 2022 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Numb |
|
| October 12, 2022 |
Exhibit 99.1 Eagle Pharmaceuticals Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CAL02, a Novel First-in-Class Broad-Spectrum Anti-Virulence Agent for the Treatment of Severe Community-Acquired Bacterial Pneumonia - Company plans to commence an adequately powered Phase 2 study with approximately 276 patients with severe community-acquired pne |
|
| October 11, 2022 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate Exhibit 4.6 ? Eagle Pharmaceuticals,?Inc. ? and ? , As Warrant Agent ? Form?of Preferred Stock Warrant Agreement ? Dated As Of ? 1 ? Eagle Pharmaceuticals,?Inc. Form?of Preferred Stock Warrant Agreement ? This Preferred Stock Warrant Agreement (this ?Agreement?), dated as of [?], between Eagle Pharmaceuticals,?Inc., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking |
|
| October 11, 2022 |
As filed with the Securities and Exchange Commission on October 11, 2022 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on October 11, 2022 Registration No. |
|
| October 11, 2022 |
Form of Common Stock Warrant Agreement and Warrant Certificate Exhibit 4.5 EAGLE PHARMACEUTICALS, INC. and , As Warrant Agent Form of Common Stock Warrant Agreement Dated As Of 1 Eagle Pharmaceuticals, Inc. Form of Common Stock Warrant Agreement This Common Stock Warrant Agreement (this ?Agreement?), dated as of [?], between Eagle Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organized a |
|
| October 11, 2022 |
Exhibit 4.3 Eagle Pharmaceuticals, Inc., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 20 Debt Securities Table Of Contents Page article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee?s Certificate 8 |
|
| October 11, 2022 |
Form of Debt Securities Warrant Agreement and Warrant Certificate Exhibit 4.7 Eagle Pharmaceuticals, Inc. and , As Warrant Agent Form of Debt Securities Warrant Agreement Dated As Of Eagle Pharmaceuticals, Inc. Form of Debt Securities Warrant Agreement This Debt Securities Warrant Agreement (this ?Agreement?), dated as of [?], between Eagle Pharmaceuticals, Inc. a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organ |
|
| October 11, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Eagle Pharmaceuticals, Inc. |
|
| October 3, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2022 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Numbe |
|
| October 3, 2022 |
Exhibit 99.1 For Immediate Release Eagle Pharmaceuticals and Enalare Therapeutics Announce FDA Orphan Drug Designation for ENA-001 for the Treatment of Apnea of Prematurity, a New Chemical Entity Being Developed as an Agnostic Respiratory Stimulant - ENA-001, with a novel mechanism of action as an agnostic respiratory stimulant, has previously been granted Rare Pediatric Disease Designation for th |
|
| September 27, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2022 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Nu |
|
| September 27, 2022 |
Exhibit 99.1 For Immediate Release Eagle Pharmaceuticals and Enalare Therapeutics Announce Additional Award Worth Up to $50 Million from BARDA to Advance an Intramuscular (?IM?) Formulation of ENA-001 - ENA-001, a new chemical entity with a unique mechanism of action, is being developed as an agnostic respiratory stimulant for use in multiple patient populations experiencing acute respiratory depr |
|
| August 25, 2022 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2022 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Comm |
|
| August 25, 2022 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.2 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Introduction The following unaudited pro forma condensed combined financial information (the ?Pro Forma Financial Information?), which includes the unaudited pro forma combined statement of operations for the six months ended June 30, 2022 and for the year ended December 31, 2021 (the ?pro forma statement of operations?), ha |
|
| August 25, 2022 |
Report of Independent Auditors Exhibit 99.1 Report of Independent Auditors To the Management and the Board of Directors of Acacia Pharma Group Limited Opinion We have audited the accompanying consolidated financial statements of Acacia Pharma Group Limited (formerly known as Acacia Pharma Group plc) and its subsidiaries (the ?Group?), which comprise the consolidated statements of financial position as of 31 December 2021 and 20 |
|
| August 18, 2022 |
Federal Circuit Rules in Favor of Eagle Pharmaceuticals in Vasopressin Litigation Exhibit 99.1 For Immediate Release Federal Circuit Rules in Favor of Eagle Pharmaceuticals in Vasopressin Litigation WOODCLIFF LAKE, N.J. ? August 18, 2022 ? Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (?Eagle? or the ?Company?) today announced that the U.S. Court of Appeals for the Federal Circuit affirmed the U.S. District Court for the District of Delaware?s decision that Eagle?s vasopressin pro |
|
| August 18, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2022 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Numbe |
|
| August 9, 2022 |
Exhibit 10.2 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Security Purchase Option Agreement This Security Purchase Option Agreement (the ?Agreement?) is entered into as of August 8, 2022 (the ?Effective Dat |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2022 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Number |
|
| August 9, 2022 |
Exhibit 99.1 For Immediate Release Eagle Pharmaceuticals Reports Second Quarter 2022 Results ? Q2 2022 net loss was $(0.74) per basic and diluted share and adjusted non-GAAP net income was $1.58 per basic and $1.56 per diluted share ? Total revenue for Q2 2022 was $74.1 million, compared to $48.1 million in Q2 2021, primarily reflecting product sales of vasopressin and PEMFEXY? ? First half 2022 a |
|
| August 9, 2022 |
Exhibit 10.1 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement, dated as of August 8, 2022 (the ?Agreement?), is by and between Enalare Therapeutic |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36306 Eagle Pharmaceuticals, |
|
| August 9, 2022 |
Exhibit 10.3 DATED June 9, 2022 Guarantee and indemnity between EAGLE PHARMACEUTICALS, INC. and COSMO TECHNOLOGIES LTD 266602710 v6 CONTENTS CLAUSE 1. Interpretation 2 2. Guarantee and indemnity 4 3. Representations and warranties 8 4. Payments 9 5. Severance 10 6. Notices 10 7. Variation, waiver and remedies 11 8. Assignment 12 9. Third party rights 12 10. Counterparts 12 11. Termination 12 12. G |
|
| August 9, 2022 |
Exhibit 99.2 For Immediate Release Eagle Pharmaceuticals Takes Equity Stake in, with Option to Acquire, Enalare Therapeutics to Advance Global Development of ENA-001, a Novel Agnostic Respiratory Stimulant - ENA-001 is currently in development for: post-operative respiratory depression, community drug overdose, and Apnea of Prematurity - - Approval for post-operative respiratory depression expecte |
|
| August 4, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2022 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction (Commission File Number) |
|
| August 1, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2022 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction (Commission File Number) (I |
|
| July 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2022 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Number) |
|
| July 18, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2022 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Number) |
|
| July 18, 2022 |
Eagle Pharmaceuticals Appoints Debra M. Hussain as SVP, Head of Commercial Exhibit 99.1 Eagle Pharmaceuticals Appoints Debra M. Hussain as SVP, Head of Commercial WOODCLIFF LAKE, NJ?July 18, 2022?Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (?Eagle? or the ?Company?) today announced the appointment of Debra M. Hussain as Senior Vice President, Head of Commercial. ?We are very pleased with our acquisition of Acacia Pharma Group plc (?Acacia?) and its two commercial products |
|
| June 15, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549? SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.????? ) Filed by the Registrant?? Filed by a Party other than the Registrant?? Check the appropriate box: Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rul |
|
| June 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| June 9, 2022 |
Exhibit 99.1 Acacia Pharma Group PLC THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION FOR IMMEDIATE RELEASE 9 June 2022, 1.00 p.m. (Brussels time) RECOMMENDED ACQUISITION of A |
|
| June 9, 2022 |
Exhibit 99.3 © 2022 Eagle Pharmaceuticals, Inc. All rights reserved. 1 1 Company Overview June 9, 2022 The information set forth herein is as of the date of the presentation and is based and conditioned on activities and review which remain ongoing, including FDA review and patent litigation, and is therefore subject to change. 2 © 2022 Eagle Pharmaceuticals, Inc. All rights reserved. Forward - Lo |
|
| June 9, 2022 |
Exhibit 99.2 For Immediate Release Eagle Pharmaceuticals Completes Acquisition of Acacia Pharma Group plc, Expanding Acute Care Footprint ? Adds two U.S. Food and Drug Administration (?FDA?) approved new chemical entities with strong patent protection ? BARHEMSYS? (amisulpride for injection) and BYFAVO? (remimazolam for injection) join Eagle portfolio, with an estimated combined $3.1 billion per y |
|
| June 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2022 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Number) |
|
| June 7, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2022 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Number) |
|
| June 7, 2022 |
Exhibit 99.1 Acacia Pharma Group PLC THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AND REGULATED INFORMATION NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION FOR IMMEDIATE RELEASE 7 June 2022, 1 p.m. (Brussels time) RECOMMEN |
|
| June 1, 2022 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2022 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Number) |
|
| June 1, 2022 |
Exhibit 99.1 For Immediate Release Eagle Pharmaceuticals Announces Submission of New Drug Application to U.S. Food and Drug Administration for Landiolol, a Beta-1 Adrenergic Blocker - Submission seeks approval for landiolol for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter - - Expected approval mid-year |
|
| May 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2022 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Number) |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36306 Eagle Pharmaceuticals |
|
| May 9, 2022 |
Exhibit 99.1 For Immediate Release Eagle Pharmaceuticals Reports First Quarter 2022 Results ? Q1 2022 net income was $3.47 per basic and $3.41 per diluted share and adjusted non-GAAP net income* was $4.10 per basic and $4.04 per diluted share ? Q1 2022 total revenue was $115.9 million, up from $41.2 million in Q1 2021 ? Achieved sales of $34.3 million of vasopressin, with prior four weeks average |
|
| May 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2022 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Number) ( |
|
| May 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to .. Commission File Number 001- |
|
| April 27, 2022 |
Exhibit 99.1 PRIVILEGED & CONFIDENTIAL THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. PART II (EXPLANATORY STATEMENT) OF THIS DOCUMENT COMPRISES AN EXPLANATORY STATEMENT IN COMPLIANCE WITH SECTION 897 OF THE COMPANIES ACT 2006. This Document contains a proposal which, if implemented, will result in the cancellation of the listing and trading of Acacia Shares on Euronext Brussels |
|
| April 27, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2022 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Number |
|
| April 19, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2022 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Number |
|
| April 19, 2022 |
Exhibit 99.1 For Immediate Release Eagle Pharmaceuticals Reaches Settlement Agreement with Hospira Related to BENDEKA® (bendamustine hydrochloride) until January 17, 2028 WOODCLIFF LAKE, N.J. — April 19, 2022 — Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it has reached a settlement agreement with Hospira, Inc (“Hospira”). Eagle had asserted two Orange |
|
| March 31, 2022 |
Exhibit 99.1 CONFIDENTIAL AND INTERNAL ? 2022 Eagle Pharmaceuticals, Inc. All rights reserved. 1 Investor Update 3/31/2022 CONFIDENTIAL AND INTERNAL ? 2022 Eagle Pharmaceuticals, Inc. All rights reserved. 2 Forward - Looking Statements This presentation contains ?forward - looking statements? within the meaning of the Private Securities Litigation Reform Act of 19 95, as amended, and other securit |
|
| March 31, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2022 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Number |
|
| March 28, 2022 |
Exhibit 10.3 LOCK-UP AGREEMENT This lock-up agreement, dated March 27, 2022 (this ?Agreement?), by and between the undersigned holder (the ?Holder?) and Eagle Pharmaceuticals, Inc., a Delaware corporation (the ?Buyer?), is being executed and delivered in connection with the co-operation agreement, dated as of March 27, 2022 (the ?Co-operation Agreement?), by and among the Buyer and Acacia Pharma G |
|
| March 28, 2022 |
Eagle Pharmaceuticals Agrees to Terms to Acquire Acacia Pharma Group plc Exhibit 99.1 For Immediate Release Eagle Pharmaceuticals Agrees to Terms to Acquire Acacia Pharma Group plc ? Expects to add two U.S. Food and Drug Administration (?FDA?)-approved, new chemical entities (?NCEs?) with patent life into 2031 and expand acute care footprint ? Commercialized assets, BARHEMSYS? (amisulpride for injection) and BYFAVO? (remimazolam for injection), represent a strong strat |
|
| March 28, 2022 |
Form of Shareholder Undertaking. EX-10.1 4 tm2210534d1ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 DEED OF IRREVOCABLE UNDERTAKING – SHAREHOLDER To: Eagle Pharmaceuticals, Inc. (“Eagle”) 50 Tice Blvd, Suite 315 Woodcliff Lake NJ 07677 USA From: [Name of shareholder] [Address] March 2022 Dear Sirs and Madams, Proposed acquisition of the entire issued and to be issued share capital of Acacia Pharma Group plc (the “Company”) by Eagle 1. We |
|
| March 28, 2022 |
Exhibit 10.2 DEED OF IRREVOCABLE UNDERTAKING ? DIRECTOR To: Eagle Pharmaceuticals, Inc. (?Eagle?) 50 Tice Blvd, Suite 315 Woodcliff Lake NJ 07677 USA From: [Name of director] [Address] March 2022 Dear Sirs and Madams, Proposed acquisition of the entire issued and to be issued share capital of Acacia Pharma Group plc (the ?Company?) by Eagle 1. I understand that Eagle intends to make an offer to ac |
|
| March 28, 2022 |
Form of Shareholder Lock-up Agreement. Exhibit 10.4 LOCK-UP AGREEMENT This lock-up agreement, dated March , 2022 (this ?Agreement?), by and between the undersigned holder (the ?Holder?) and Eagle Pharmaceuticals, Inc., a Delaware corporation (the ?Buyer?), is being executed and delivered in connection with the co-operation agreement, dated as of March , 2022 (the ?Co-operation Agreement?), by and among the Buyer and Acacia Pharma Group |
|
| March 28, 2022 |
EX-2.2 3 tm2210534d1ex2-2.htm EXHIBIT 2.2 Exhibit 2.2 Execution version Dated 27 March 2022 Eagle Pharmaceuticals, Inc. and Acacia Pharma Group PLC CO-OPERATION AGREEMENT relating to THE PROPOSED SCHEME OF ARRANGEMENT OF ACACIA PHARMA GROUP PLC Contents 1. Interpretation 1 2. Publication of the Announcement and the terms of the Scheme 9 3. Conditions 9 4. Obligations of the Company 10 5. Scheme Do |
|
| March 28, 2022 |
Announcement, dated March 28, 2022. EX-2.1 2 tm2210534d1ex2-1.htm EXHIBIT 2.1 Exhibit 2.1 ACACIA PHARMA GROUP PLC PROPOSED TRANSACTION WITH EAGLE PHARMACEUTICALS, INC. THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION AND INSIDE INFORMATION Not for release, publication or distribution, in whole or in part, directly or indirectly in, into or from any jurisdiction where to do so would constitute a violation of the relevant laws of such |
|
| March 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2022 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Number |
|
| March 25, 2022 |
Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-8 Eagle Pharmaceuticals, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered(1) Proposed Maximum Offering Price Per Share Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.001 per share, reserved for issuance pursuan |
|
| March 25, 2022 |
As filed with the Securities and Exchange Commission on March 25, 2022 As filed with the Securities and Exchange Commission on March 25, 2022 Registration No. |
|
| March 8, 2022 |
List of subsidiaries of Eagle Pharmaceuticals, Inc. EX-21 2 exhibit21110k2021.htm EX-21 Exhibit 21.1 Subsidiaries of Eagle Pharmaceuticals, Inc. Name of Subsidiary Jurisdiction of Incorporation Eagle Biologics, Inc. (formerly Arsia Therapeutics, Inc.) Delaware Eagle Research Lab Limited Malta |
|
| March 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-36306 Eagle Pharmac |
|
| March 7, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2022 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Number) |
|
| March 7, 2022 |
Exhibit 99.1 For Immediate Release Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Results ? Q4 2021 net loss was $(0.48) per basic and diluted share and adjusted non-GAAP net income* was $0.87 per basic and $0.85 per diluted share ? FY 2021 net loss was $(0.66) per basic and diluted share and adjusted non-GAAP net income* was $2.64 per basic and $2.59 per diluted share ? Early tre |
|
| February 14, 2022 |
EGRX / Eagle Pharmaceuticals Inc / Park West Asset Management LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* EAGLE PHARMACEUTICALS, inc. (Name of Issuer) Common Stock, PAR VALUE $0.001 per share (Title of Class of Securities) 269796108 (CUSIP Number) DECEMBER 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 14, 2022 |
EGRX / Eagle Pharmaceuticals Inc / Tarriff Scott - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7)* Eagle Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 269796108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 9, 2022 |
EGRX / Eagle Pharmaceuticals Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Eagle Pharmaceuticals Inc./DE Title of Class of Securities: Common Stock CUSIP Number: 269796108 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| February 1, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2022 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Numb |
|
| February 1, 2022 |
Exhibit 99.1 For Immediate Release Eagle Pharmaceuticals Announces Commercial Availability of PEMFEXY? - Sales of PEMFEXY (pemetrexed for injection) commence today - - ALIMTA? U.S. market totaled $1.2 billion for the twelve months ended September 30, 2021 - - Launch expected to drive significant revenue growth in 2022 - WOODCLIFF LAKE, N.J. ? February 1, 2022 ? Eagle Pharmaceuticals, Inc. (Nasdaq: |
|
| January 31, 2022 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2022 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Numb |
|
| January 31, 2022 |
EX-99.1 2 tm224831d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 For Immediate Release Eagle Pharmaceuticals on Track to Support Submission of New Drug Application in Second Quarter 2022 for Landiolol, a Beta-1 Adrenergic Blocker -Anticipate Landiolol to become market leader in this drug class - WOODCLIFF LAKE, N.J. — January 31, 2022 — Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) |
|
| January 18, 2022 |
Exhibit 99.1 For Immediate Release Eagle Pharmaceuticals Announces Commercial Availability of Vasopressin - Shipment of vasopressin, a generic alternative to Vasostrict?, commences today, with 180 days of marketing exclusivity - - Product launch expected to drive significant revenue growth in 2022 - WOODCLIFF LAKE, N.J. ? January 18, 2022 ? Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (?Eagle? or th |
|
| January 18, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2022 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Numb |
|
| January 11, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2022 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Numb |
|
| January 11, 2022 |
EX-99.1 2 tm222580d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 CONFIDENTIAL AND INTERNAL © 2022 Eagle Pharmaceuticals, Inc. All rights reserved. 1 1 Company Overview January 2022 CONFIDENTIAL AND INTERNAL © 2022 Eagle Pharmaceuticals, Inc. All rights reserved. 2 Forward - Looking Statements This presentation contains “forward - looking statements” within the meaning of the Private Securities Litigation |
|
| January 5, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2022 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Numbe |
|
| January 5, 2022 |
Exhibit 99.1 For Immediate Release Eagle Pharmaceuticals Provides 2022 Business Update and Announces Launch of Vasopressin - Vasopressin shipments scheduled to commence January 17, 2022 - - Together with upcoming launch of PEMFEXY? and advancements in pipeline, significant revenue growth expected this year - WOODCLIFF LAKE, N.J. ? January 5, 2022 ? Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (?Eagl |
|
| December 29, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2021 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Num |
|
| December 29, 2021 |
Eagle Pharmaceuticals Receives 180 Days of Marketing Exclusivity for Recently Approved Vasopressin EX-99.1 2 tm2136523d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 For Immediate Release Eagle Pharmaceuticals Receives 180 Days of Marketing Exclusivity for Recently Approved Vasopressin WOODCLIFF LAKE, N.J. — December 29, 2021 — Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the U.S. Food and Drug Administration has determined that the Company has maintained it |
|
| December 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 27, 2021 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Num |
|
| December 20, 2021 |
Exhibit 99.1 For Immediate Release Eagle Pharmaceuticals Reports that Par Has Unilaterally Withdrawn Attempt to Halt Launch of Vasopressin WOODCLIFF LAKE, N.J. ? December 20, 2021 ? Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (?Eagle? or the ?Company?) today announced that Par Pharmaceutical, Inc. (?Par?) has unilaterally withdrawn its request that the U.S. District Court for the District of Delawa |
|
| December 20, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2021 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Num |
|
| December 15, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2021 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Num |
|
| December 15, 2021 |
Exhibit 99.1 For Immediate Release Eagle Pharmaceuticals Receives FDA Approval for Vasopressin - Company is first to file an ANDA referencing Vasostrict?, which had total U.S. sales of $786 million in 2020 - WOODCLIFF LAKE, N.J. ? December 15, 2021 ? Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (?Eagle? or the ?Company?) today announced that the U.S. Food and Drug Administration (?FDA?) has approved |
|
| November 9, 2021 |
Exhibit 10.1 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. CONFIDENTIAL Execution Copy LICENSE AGREEMENT BETWEEN EAGLE PHARMACEUTICALS, INC. AND COMBIOXIN SA 259471316 v2 259471316 v2 LICENSE AGREEMENT THIS LICENSE AGREEMENT (?A |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36306 Eagle Pharmaceuti |
|
| November 9, 2021 |
Exhibit 99.1 For Immediate Release Eagle Pharmaceuticals Reports Third Quarter 2021 Results ????????Q3 2021 net loss was $0.43 per basic and diluted share and adjusted non-GAAP net income was $0.57 per basic and $0.56 per diluted share ????????Expect to receive approval for Abbreviated New Drug Application (?ANDA?) for vasopressin; December 15, 2021 GDUFA date ????????Received favorable district c |
|
| November 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2021 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Numb |
|
| November 9, 2021 |
Exhibit 10.2 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. CONFIDENTIAL LICENSE AGREEMENT BETWEEN AOP ORPHAN PHARMACEUTICALS GmbH AND EAGLE PHARMACEUTICALS, INC. LICENSE AGREEMENT THIS LICENSE AGREEMENT (this ?Agreement?) dated |
|
| November 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No.1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2021 (September 27, 2021) Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or oth |
|
| October 14, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 14, 2021 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Numb |
|
| October 14, 2021 |
1 1 Company Overview October 2021 Exhibit 99.2 1 1 Company Overview October 2021 2 Forward - Looking Statements This presentation contains forward - looking information within the meaning of the Private Securities Litigation Reform Act of 199 5, as amended, and other securities laws. Forward - looking statements are statements that are not historical facts. Words and phrases such as ?anticipated,? ?forward,? ?will,? ?would,? ?may, |
|
| October 14, 2021 |
1 1 Company Overview October 2021 Exhibit 99.1 1 1 Company Overview October 2021 2 Forward - Looking Statements This presentation contains forward - looking information within the meaning of the Private Securities Litigation Reform Act of 199 5, as amended, and other securities laws. Forward - looking statements are statements that are not historical facts. Words and phrases such as ?anticipated,? ?forward,? ?will,? ?would,? ?may, |
|
| October 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2021 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Nu |
|
| September 9, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2021 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Num |
|
| September 9, 2021 |
Exhibit 99.1 1 1 CAL02 Investor Update September 9, 2021 2 Forward-Looking Statements This presentation contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and other securities laws. Forward-looking statements are statements that are not historical facts. Words and phrases such as ?anticipated,? ?forward,? ?will,? ?would,? ?m |
|
| August 31, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2021 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Numbe |
|
| August 31, 2021 |
Eagle Pharmaceuticals Wins Vasopressin Patent Trial Exhibit 99.1 For Immediate Release Eagle Pharmaceuticals Wins Vasopressin Patent Trial WOODCLIFF LAKE, N.J. ? August 31, 2021 ? Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (?Eagle? or the ?Company?) today announced that the U.S. District Court for the District of Delaware held that Eagle?s proposed vasopressin product does not infringe any of the patents Par asserted against the Company. Eagle is f |
|
| August 31, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2021 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Numbe |
|
| August 31, 2021 |
Eagle Pharmaceuticals Granted Additional Patent for Bendamustine Franchise Exhibit 99.1 For Immediate Release Eagle Pharmaceuticals Granted Additional Patent for Bendamustine Franchise WOODCLIFF LAKE, N.J. ? August 31, 2021 ? Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (?Eagle? or the ?Company?) today announced that the U.S. Patent and Trademark Office has granted the Company U.S. Patent No. 11,103,483, entitled ?Formulations of Bendamustine.? Eagle is submitting the ?483 |
|
| August 25, 2021 |
Exhibit 99.1 For Immediate Release Eagle Pharmaceuticals Announces Worldwide Licensing Agreement with Combioxin SA for Phase 2b/3, Novel First-in-Class Antitoxin Agent CAL02 in Development for Combination Use with Antibiotics for the Treatment of Severe Pneumonia - CAL02 neutralizes toxic virulence effectors (?VEs?) produced by bacteria; VEs play a decisive role in the development of long-term, se |
|
| August 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2021 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Numbe |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2021 Eagle Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36306 20-8179278 (State or other jurisdiction of (Commission File Number |
|
| August 9, 2021 |
Exhibit 99.1 For Immediate Release Eagle Pharmaceuticals Reports Second Quarter 2021 Results Q2 2021 net income was $0.28 per basic and $0.27 per diluted share and adjusted non-GAAP net income was $0.95 per basic and $0.93 per diluted share Announced licensing agreement for U.S. commercial rights to Landiolol, a beta-1 adrenergic blocker and a leading hospital emergency use product in Europe and J |
